Why the study?
Current antiplatelet drugs targeting integrin αIIbβ3 or its upstream signaling increase the risk of serious spontaneous bleeding, creating a need for safer antithrombotic strategies that prevent thrombosis without impairing normal hemostasis.
Does an antibody targeting the β-tail domain of integrin β3 prevent thrombosis without inducing bleeding in preclinical models?
Population
Ex vivo and in vivo models
Comparison
Antibody targeting the β-tail domain of integrin β3
Design
Preclinical experimental study
Key result
An antibody targeting the β-tail domain of integrin β3 suppressed platelet aggregation in ex vivo and in vivo models without inducing bleeding.
Authors
Loading...
May enable antithrombotic benefit without bleeding risk; extends β-tail domain targeting of integrin β3 as selective therapeutic strategy.
Does an antibody targeting the β-tail domain of integrin β3 prevent thrombosis without inducing bleeding in preclinical models?
Targeting the β-tail domain of integrin β3 to selectively block force-induced activation provides a promising antithrombotic strategy that minimizes bleeding risk.
Lee et al. (2026) studied Thrombosis. Antibody targeting the β-tail domain of integrin β3 was evaluated on Platelet aggregation and bleeding. An antibody targeting the β-tail domain of integrin β3 suppressed platelet aggregation in ex vivo and in vivo models without inducing bleeding.